Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Abstract excerpt

Early-stage cutaneous T-cell lymphoma (CTCL) is a skin-limited lymphoma with no cure aside from stem cell transplantation. Twelve patients with stage IA-IIA CTCL were treated in a phase 1 trial of 0.03% and 0.06% topical resiquimod gel, a Toll-like receptor 7/8 agonist. Treated lesions significantly improved in 75% of patients and 30% had clearing of all treated lesions. Resiquimod also induced regression of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous lymphoproliferative disorders research
• Share to Fungal Infections and Studies
• Share to Nail Diseases and Treatments